As the death toll of West Africa's Ebola outbreak reaches 2,500, GlaxoSmithKline's experimental Ebola vaccine is being tested at the U.S. National Institutes of Health with no apparent ill effects so far, health officials report.
Pharma companies are increasingly relying on academic and nonprofit collaborations for basic science and drug discovery research, and some big players have formed some notable unions in 2014.
The discovery of a new HIV antibody highlights the need to create vaccines with trimeric delivery systems that resemble those found naturally, said Mark Connors, the research team's principal investigator and chief of the HIV-Specific Immunity Section.
The U.S. government hasn't seen the last of its laboratory safety woes. Following a handful of accidents involving the mismanagement of highly infectious pathogens at federal facilities in recent months, the National Institutes of Health revealed on Sept. 5 that it uncovered small amounts of other improperly stored pathogens--including the toxin ricin and plague-causing bacteria.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
Wet age-related macular degeneration is the leading cause of blindness in the developed world. The standard of care calls for about 8 costly injections into the eye of medication containing anti-VEGF (vascular endothelial growth factor) per year. "In the real world having patients maintain that level of monitoring and therapy just does not happen," Jim Taylor, who has struggled to convince his aging mother to receive the therapy, told FierceMedicalDevices in an interview.
The National Institutes of Health (NIH) has awarded $14.5 million in eight grants to researchers working to develop high quality and low cost DNA sequencing. The grants are each for two to four years and are awarded through the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute, a part of NIH.
While Google-backed personal genetics startup 23andMe is still working through its disagreements with the FDA, the company has impressed another part of the federal machine enough to win funding.
A decade of flat funding compounded by last year's federal sequester cuts has put U.S. biomedical research in a pinch in recent years, but under a new bill the National Institutes of Health would be spared the budget ax.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.